Brief: European Commission Approves Kimmtrak For Treatment Of Unresectable Or Metastatic Uveal Melanoma

Immunocore Holdings

04/04/2022 12:26

April 4 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * EUROPEAN COMMISSION APPROVES KIMMTRAK® (TEBENTAFUSP) FOR
THE
TREATMENT OF UNRESECTABLE OR METASTATIC UVEAL MELANOMA

Source text for Eikon:  ID:nGNX9hJLHC 
Further company coverage:  IMCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))